Please login to the form below

Not currently logged in
Email:
Password:

Actavis makes two additions to board of directors

Michael R Gallagher and Peter J McDonnell join

Actavis has elected Michael R Gallagher and Peter J McDonnell to its board of directors.

Both Gallagher and McDonnell are former members of the board of directors for Allergan, whom Actavis completed its acquisition of this week.

Brent Saunders, CEO and president and Actavis, commented: “The addition of Michael and Peter brings significant experience from Allergan to our board and I welcome their insights and expertise as we combine our two dynamic organisations.

“I want to thank the entire Allergan board for their stewardship to Allergan shareholders in building a strong and successful company.”

Gallagher was elected to the Allergan board in 1998 and served as its lead independent director and chair of the organisation and compensation committee. 

In 2004, he retired as CEO and director of Playtex products where he joined in 1995. Prior to this, he held a number of senior roles at companies including Procter & Gamble and Reckitt & Colman.

McDonnell was appointed to the Allergan board in 2013 and served on the corporate governance and compliance committee and the science and technology committee. 

He has served as the chief medical editor of Ophthalmology Times and his research interests include the causes and correction of refractive error, corneal wound healing and microbial keratitis. 

20th March 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics